Olympus Company (Director, Consultant Executive Officer, President and CEO: Yasuo Takeuchi) right now declared the launch of ENDO-Assist*1, a slicing-edge platform powered by synthetic intelligence (AI) that features the endoscopy software ENDO-Assist CADe (computer-aided detection) for the colon.
This new AI platform permits serious-time show of quickly detected suspicious lesions and is effective in combination with Olympus’ lately released EVIS X1, its most sophisticated endoscopy procedure to day.
As a global leader in planning and offering impressive alternatives for health care and surgical strategies, Olympus aims to make improvements to the health and fitness and good quality of life of individuals by furnishing sophisticated health care technologies. Its latest endoscopy procedure, EVIS X1, was developed to set new standards for picture detection, characterization, staging, and therapy.
With the recently released endoscopy CAD (computer-aided detection/prognosis) platform ENDO-Assist, Olympus is now maximizing the abilities of EVIS X1 by AI engineering, aiming to elevate the standard of endoscopy all-around the globe – whether for programs to disorders of the esophagus, stomach, colon or other gastrointestinal organs.
ENDO-Assist CADe: serious-time computer-aided detection for endoscopy
ENDO-Assist CADe is an software for computer-aided detection powered by AI which operates on ENDO-Assist. It uses a sophisticated algorithm by means of a neural network developed and experienced by Olympus. With this new software, the system’s subtle machine discovering can inform the endoscopist in serious time when a suspected colonic lesion (this kind of as a polyp, malignant neoplasm or adenoma) appears on the display.
ENDO-Assist CADe was developed towards the subsequent advancements:
- Improved observational efficiency in adenoma detection: By furnishing visible assist, ENDO-Assist CADe aims to make improvements to the observational efficiency of the endoscopist’s adenoma detection.
- Assist of the colonoscopy screening process: The procedure supplies visible assist throughout screening, letting the endoscopist to focus on any abnormalities indicated by the software package regardless of the encounter level of the endoscopist.
- Successful endoscopy procedure: Because of to the easy and intuitive show of lesions, ENDO-Assist CADe has the probable to make endoscopy easier and additional effective for the endoscopist by lowering the will need for extreme eye actions.
A very first action in the direction of the upcoming of endoscopic prognosis and treatment
With ENDO-Assist, the latest function of the EVIS X1 endoscopy procedure, Olympus has produced the foundation and infrastructure for the installation of upcoming programs supported by AI. “At Olympus we are fully commited to innovation and driving our study and advancement with enthusiasm,” says Frank Drewalowski, Head of Endoscopic Answers Division, Olympus Company. “Especially in AI, we recognize the power of elevating endoscopic imaging to uncharted amounts. Thinking of ENDO-Assist as a very first action, we are organizing supplemental AI-powered programs for picture detection and characterization – not only for colonoscopy.”
Avoidance of colorectal cancer remains our focus
There is a beneficial impression of an increase in adenoma detection charge (ADR) on the avoidance of colorectal cancer (CRC)*two. Supporting the identification of lesions, ENDO-Assist CADe is made to increase ADR*three. We are aiming to increase the good quality of CRC screening and its preventive efficacy towards CRC. The avoidance of CRC is a core aspect of Olympus’ endeavors in health care endoscopy and past.
“With the launch of ENDO-Assist, we are not only furnishing endoscopists throughout the globe with an supplemental impressive software,” says Takaharu Yamada, Vice President, GI Endoscopy Business Chief, Endoscopic Answers Division. “We are also preparing for the upcoming and subsequent our vision of placing CRC in the record guides.”
Formal launch at United European Gastroenterology Week (UEGW)
All through the digital UEGW from Oct 11 to 13, ENDO-Assist will be introduced to the community for the very first time. ENDO-Assist is in the beginning and commercially getting launched in Europe commencing in November, adopted soon later on by some Middle Japanese, African and Asian-Pacific countries. Japan, the Americas and China marketplaces will abide by at a afterwards time soon after complying with rules and polices in every single area. EVIS X1 and ENDO-Assist are created by Olympus Clinical Units Company. The business and item names specified in this release are the emblems or registered emblems of Olympus.
*1 Item Title: Endoscopy CAD procedure
*two Corley, D.A. Jensen, C.D. Marks, A.R. et al. Adenoma Detection Rate and Danger of Colorectal Cancer and Demise. N Engl J Med. 2014 370: 1298-1306. Offered at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036494/. Accessed in Oct 2020
*three Compared to WLI (white gentle imaging) with out CADe
Olympus is passionate about the alternatives it results in for the health care, life sciences, and industrial equipment industries, as properly as cameras and audio items. For additional than 100 yrs, Olympus has centered on producing people’s lives more healthy, safer, and additional satisfying by helping detect, protect against, and address disorder, furthering scientific study, making sure community safety, and capturing visuals of the globe.
Olympus Endoscopic Answers uses impressive abilities in health care engineering, therapeutic intervention, and precision manufacturing to assist healthcare experts produce diagnostic, therapeutic, and minimally invasive strategies to make improvements to scientific outcomes, reduce overall costs, and increase the good quality of life for individuals. Setting up with the world’s very first gastrocamera in 1950, Olympus’ endoscopic portfolio has developed to contain endoscopes, laparoscopes, and online video imaging units, as properly as units integration alternatives and health care expert services.